Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography/ tandem mass spectrometry

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic drug monitoring is a cornerstone of antibacterial therapy, especially in an era of increasing antibacterial resistance in individualizing antimicrobial therapy. Liquid chromatography/tandem mass spectrometry (LC–MS/MS) assay was used for the simultaneous measurement of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in 50 ml plasma samples over a wide range. The overall turnaround time for the assay was 20 minutes. Intra-assay precision and accuracy for quality control samples ranged within 1.8–8.5 and 91.4–106.7%, respectively. Inter-assay precision and accuracy ranged within 1.3–14.4 and 95.8–104.6%, respectively. The lower limit of quantification was below 1.5 mg/ml for all the five antibiotics. No ion suppression due to matrix effects was found. A simple and rapid LC–MS/MS method which provides high specificity, precision and accuracy for the simultaneous quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma has been developed and validated. The present method is suitable for therapeutic drug monitoring in paediatrics.

Original languageEnglish
Pages (from-to)343-347
Number of pages5
JournalJournal of Chemotherapy
Volume27
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Keywords

  • Ceftazidime
  • Linezolid
  • Liquid chromatography/tandem mass spectrometry
  • Meropenem
  • Piperacillin
  • Tazobactam

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography/ tandem mass spectrometry'. Together they form a unique fingerprint.

Cite this